You have a chance to get positioned before institutional access to $INJ gets easier 21Shares just updated its proposed Injective ETF filing And this is what stands out: → The fund plans to stake 40–60% of its $INJ holdings → Proposed Nasdaq ticker: $TINJ → Uses the FTSE Injective Index to price $INJ → BNY Mellon would handle administration, transfers and cash custody What does this mean? It means the structure for giving traditional investors exposure to $INJ through an ETF is becoming more defined If approved, investors could get Injective exposure without directly buying and managing Injective themselves Institutional access to Injective is taking shape.